coteauBeta Get App

EVMN

Evommune, Inc.
$5.21
+0.77% Oct 22 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-75%-40%-5%+29%+64%Nov 2025Oct 2026Apr 202652w high $33.2052w low $5.09
EVMNSPY
1W
-12.1%
1M
-45.7%
3M
-54.0%
6M
-79.8%
YTD
-69.6%
1Y
–

Live chart

Loading live chart…

What they do

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for EVMN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
GlobeNewswire · Oct 19
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target
MT Newswires · Oct 12
EADV26: Key late-stage readouts from the conference
Clinical Trials Arena · Oct 05
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Business Wire · Oct 01
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Business Wire · Sep 23

Key stats

Market value$187.6M
P/E (next 12 months, estimated)-1.5
52-week range$5.09 – $33.20
Dividend yieldNo dividend
Analyst consensusBuy (9)
Average analyst price target$22.33 (+329%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

Next report: 2026-11-16 · during market · EPS est -0.83
25-1226-0326-08-11.350.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-06-0.67-0.89-32.8%
2026-03-05-0.84-1.43-69.8%
2025-12-11-11.35-8.07+28.9%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$10.0M–
Rating changes
Initiated
2026-10-12 · UBS started covering EVMN at Neutral
Reiterated
2026-09-09 · Leerink Partners reiterated Outperform on EVMN
Reiterated
2026-09-09 · RBC Capital reiterated Outperform on EVMN
Reiterated
2026-09-09 · HC Wainwright & Co. reiterated Neutral on EVMN
Initiated
2026-08-26 · Needham started covering EVMN at Buy
Reiterated
2026-08-07 · RBC Capital reiterated Outperform on EVMN

Third-party analyst actions, not Coteau's views. All rating changes

Insider trades
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:28:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026